00013 HUTCHMED
- 31.800
- +1.450+4.78%
HUTCHMED News
HUTCHMED's Fruquintinib Close to EU Approval
Chu Wong Pharmaceutical (00013.HK): Takeda receives positive feedback from the European Medicines Agency's Human Medicines Committee (CHMP) to support fruquintinib (fruquintinib) for the treatment of metastatic colorectal cancer
On April 26, Gelonghui Pharmaceutical (00013.HK) announced that its partner Takeda (TSE: 4502/ NYSE: TAK) has obtained the recommendation of the European Medicines Agency (EMA) Commission for Human Medicines (CHMP) to approve fruquintinib for the treatment of treated adult patients with metastatic colorectal cancer. The European Commission (EC) will take the positive comments of CHMP into account when deciding on marketing licensing fruquintinib for the treatment of metastatic colorectal cancer throughout the European Union, Norway, Liechtenstein, and Iceland. If approved, furoquine
Express News | HUTCHMED Announces CHMP Opinion For Fruquintinib In Previously Treated Metastatic Colorectal Cancer Received By Takeda
HUTCHMED (China) (LON:HCM) Shareholders Are up 8.2% This Past Week, but Still in the Red Over the Last Five Years
Changes in Hong Kong stocks | Hutchison Pharmaceutical (00013) rose nearly 7% in the afternoon, and the volume of furoquintinib was rapidly released after launch, and many major products are expected to be approved for major indications
Hewang Pharmaceutical (00013) rose nearly 7% in the afternoon. As of press release, it had risen 6.13% to HK$28.55, with a turnover of HK$94.6406 million.
The biomedical sector gained strength in the afternoon, and Pharmaceutical Federation (02268) rose 8.59%. Institutions say the industry still has structural growth this year
Jinwu Financial News | The biomedical sector gained strength in the afternoon, with Pharmaceuticals (02268) up 8.59%, Rongchang Biotech (09995) up 6.53%, Cinda Biotech (01801) up 6.48%, Cansino Biotech (06185) 6.4%, Viva Biotech (01873) 5.88%, Hehuang Pharmaceutical (00013) up 5.58%, and Kang Fang Biotech (09926) up 5.41%. Huaxin Securities said that the growth of the industry in the first quarter of 2024 was clearly affected by the base for the same period, such as retail pharmacies, POCT, etc., and the outlook is for the whole of 2024.
HUTCHMED Announces Key Managerial LTIP Vesting
HUTCHMED Executives' Incentive Plan Vested
Changes in Hong Kong stocks | Hutchison Pharmaceutical (00013) is now up nearly 6%. The company announced data at the AACR annual meeting that furoquintinib was released rapidly after listing in the US
Hehuang Pharmaceutical (00013) is now up nearly 6%. As of press release, it has risen 5.21% to HK$28.25, with a turnover of HK$586.912 million.
HUTCHMED: 2023 Annual Report
HUTCHMED to Unveil New Cancer Drug Data at AACR 2024
Hutchmed to Present New Data at US Cancer Research Conference
Hutchmed (China) (HKG:0013) will present new and updated data from several studies at the upcoming American Association of Cancer Research Annual Meeting 2024, a Friday filing on the Hong Kong bourse
HUTCHMED Says Initial Preclinical Data For HMPL-506 Novel, Highly Potent And Differentiated Menin-MLL Inhibitor For The Treatment Of Certain Types Of Acute Leukemia At AACR Congress 2024
Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia. Compared with five other me
Hehuang Pharmaceutical (00013) will release data from several studies at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Hehuang Pharmaceutical (00013) issued an announcement. The group announced today that it will run from April 5, 2024 to...
Standard Biotools Enters Strategic Engagement With Bristol Myers for Expanded Use of Somascan Platform
HUTCHMED (China) And Innovent's Endometrial Cancer Treatment Granted Priority Review By NMPA
Hehuang Pharmaceutical (00013) and Cinda Biotech announce that the marketing application for fruquintinib (fruquintinib) combined with sintilimab (sintilimab) for the treatment of advanced endometrial cancer in China has been accepted and included in prio
Hehuang Pharmaceutical (00013) issued an announcement. Today, Hehuang Pharmaceutical (China) Co., Ltd. and Innovent Biologics, Inc. jointly announced that the new drug marketing application for patients with advanced mismatch repair (pMMR1) or non-microsatellite-highly unstable (non-MSI-H2) endometrial cancer patients using a combination of furoquintinib and cindilizumab to treat disease progression after previous systemic anti-tumor treatment and is not suitable for radical surgical treatment or radical radiotherapy (non-) has been accepted and prioritized by the China National Drug Administration.
Sector Update: Health Care Stocks Advance Premarket Thursday
Health care stocks were advancing premarket Thursday, with the Health Care Select Sector SPDR Fund (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) recently 0.5% higher. Akebia Therapeutics (AKBA
Hutchmed Says Supplemental New Drug Application for Savolitinib Accepted for Review in China
Hutchmed (HCM) said late Wednesday the China National Medical Products Administration has accepted for review its supplemental new drug application for savolitinib as a treatment for adult patients wi
On Wednesday, HUTCHMED Announced Savolitinib SNDA Accepted in China For Treatment-Naïve Or Previously Treated Patients With Locally Advanced Or Metastatic MET Exon 14 NSCLC
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the supplemental New Drug Application ("sNDA") for savolitinib, in adult patients with locally advanced or metastat
Analysis
Price Target
No Data
